<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>11188937</identifier>
<setSpec>0025-7680</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Bruno, S</dc:author>
<dc:description xml:lang="en">Follicular lymphomas constitute 40% of non-Hodgkin lymphomas (NHL). Most of them (85%) present the t14:18 translocation with altered expression of BCL2. The lack of clinical prognostic factors able to separate a group of patients with poor outcome have shifted the interest to the assessment of t14:18 as a molecular marker for clinical response. Moreover, the translocation site is being studied as a prognostic variable. New therapeutic modalities aimed to affect BCL2 such as the antiidiotype vaccines or antisense oligonucleotides against BCL2 have motivated great expectancy.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2000 </dc:date>
<dc:title xml:lang="es">Linfomas no Hodgkin foliculares y enfermedad residual m√≠nima.</dc:title>
<dc:title xml:lang="en">[Follicular non-Hodgkin lymphomas and minimal residual disease].</dc:title>
<dc:publisher>Medicina</dc:publisher>
</metadata>
</record>
</pubmed-document>
